ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2024
%BF, Rather Than BMI, is Associated with an Increased Risk of Sarcopenia in Hospitalized Postmenopausal Chinese Women with Type 2 Diabetes Mellitus.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unseen burden: Prevalence and determinants of possible sarcopenia in Indonesian older adults - a secondary data analysis.Belitung nursing journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the relationship between obesity indices and sarcopenia in postmenopausal patients with type 2 diabetes mellitus (T2DM) at different body mass index (BMI) levels. Patients and Methods: This retrospective cross-sectional study included 298 hospitalized postmenopausal women diagnosed with T2DM. We collected demographic, biochemical, and anthropometric data on each subject. Body composition was measured using dual-energy X-ray absorptiometry (DXA), and skeletal muscle mass index (SMI) and body fat percentage (%BF) were calculated. According to BMI stratification, the patients were divided into normal group A (18.5 kg/m Results: From group A to group C, SMI (5.21±0.56 vs 5.48±0.56 vs 6.03±0.69) increased gradually (P < 0.05). Logistic regression analysis indicated that for each 1-unit increase in BMI, the risk of sarcopenia decreased by 63.2% (OR=0.368, 95% CI 0.215-0.629, P=0.000) in group A. Age (OR=1.077, 95% CI 1.015-1.144, P=0.015) and %BF (OR=1.094, 95% CI 1.010-1.186, P=0.028) increased the risk of sarcopenia by 1.077 and 1.094 times, respectively, in group B. While every 1-unit increase in BMI, the risk of sarcopenia decreased by 35% (OR=0.650, 95% CI 0.430-0.983, P=0.041) in group B. %BF (OR=1.459, 95% CI 1.093-1.949, P=0.010) increased the risk factors of sarcopenia by 1.459 times in group C. Conclusion: In postmenopausal patients with T2DM, BMI had a protective effect on the occurrence of sarcopenia within a certain range, and with the increase of BMI, the risk of sarcopenia was increasing by increased %BF levels in overweight and obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.